
What is Claimed:

1. A pharmaceutical formulation comprising KZR-616 or a salt thereof, and a sugar, wherein KZR-616 has a structure  , and the formulation is a lyophilized formulation.

2. The formulation of claim 1, wherein KZR-616 is as a maleate salt.

3. The formulation of claim 1 or 2, having a pH of 3.0 to 4.5, as measured prior to lyophilization.

4. The formulation of claim 3, having a pH of 4.2.

5. The formulation of any one of claims 1 to 4, further comprising a succinate buffer.

6. The formulation of any one of claims 1 to 5, wherein the KZR-616 or a salt thereof is present in an amount of 100 mg/mL to 200 mg/mL based upon the weight of the KZR-616 free base.

7. The formulation of any one of claims 1 to 6, wherein the sugar is present at an amount of 1.5wt% to 3 wt%, based upon total weight of the formulation.

8. The formulation of any one of claims 1 to 7, wherein the sugar comprises mannitol, trehalose, or a combination thereof.

9. The formulation of claim 8, wherein the sugar comprises trehalose.

10. The formulation of any one of claims 1 to 9, wherein the lyophilized formulation has a moisture content of less than 1%.

11. The formulation of any one of claims 4 to 10, having a pH of 4.1 to 4.3 (as measured when reconstituted) after storage at 5°C, 25°C, or 40°C for at least six months.

12. The formulation of any one of claims 1 to 11, having a reconstitution time of less than 4.5 minutes after storage at 5°C, 25°C, or 40°C for at least six months.

13. The formulation of any one of claims 1 to 12, wherein the lyophilized formulation has a moisture content of less than 1% after storage at 5°C, 25°C, or 40°C for at least six months.

14. The formulation of any one of claims 1 to 13, wherein the KZR-616 or a salt thereof is at least 93% pure after storage at 5°C, 25°C, or 40°C for at least six months.

15. A reconstituted formulation comprising the formulation of any one of claims 1 to 14 and a solvent for reconstitution.

16. The reconstituted formulation of claim 15, wherein the solvent for reconstitution comprises water for injection (WFI) or aqueous 5% dextrose.

17. The reconstituted formulation of claim 15 or 16 having an osmolality of 275 to 325 mOsm.

18. The reconstituted formulation of any one of claims 15 to 17, having an absorption rate, as measured by $T_{1/2}$, of at least 50% faster than that of a formulation comprising KZR-616 or salt thereof and polysorbate-80.

19. The reconstituted formulation of any one of claims 15 to 18, having a C_{max} of at least 150% that of a formulation comprising KZR-616 or a salt thereof and polysorbate-80 (“PS-80 formulation”).

20. The reconstituted formulation of any one of claims 15 to 19 for use in the treatment of an immune-related disease.

21. The reconstituted formulation for use of claim 20, wherein the immune-related disease is lupus nephritis or systemic lupus erythematosus (SLE).

22. The reconstituted formulation of any one of claims 15 to 19 for use in the treatment of inflammation.